Free Trial
TSE:CPH

Cipher Pharmaceuticals (CPH) Stock Price, News & Analysis

Cipher Pharmaceuticals logo
C$16.35 -0.16 (-0.97%)
As of 09/19/2025 04:00 PM Eastern

About Cipher Pharmaceuticals Stock (TSE:CPH)

Advanced

Key Stats

Today's Range
C$16.17
C$16.54
50-Day Range
C$12.05
C$16.79
52-Week Range
C$10.61
C$18.36
Volume
32,866 shs
Average Volume
27,945 shs
Market Capitalization
C$415.19 million
P/E Ratio
35.54
Dividend Yield
N/A
Price Target
C$14.75
Consensus Rating
Moderate Buy

Company Overview

Cipher Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
9th Percentile Overall Score

CPH MarketRank™: 

Cipher Pharmaceuticals scored higher than 9% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cipher Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

  • Downside Risk

    Cipher Pharmaceuticals has a consensus price target of C$14.75, representing about 9.8% downside from its current price of C$16.35.

  • Amount of Analyst Coverage

    Cipher Pharmaceuticals has received no research coverage in the past 90 days.

  • Read more about Cipher Pharmaceuticals' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cipher Pharmaceuticals is 35.54, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 280.68.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cipher Pharmaceuticals is 35.54, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 80.50.

  • Price to Book Value per Share Ratio

    Cipher Pharmaceuticals has a P/B Ratio of 4.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for CPH.
  • Dividend Yield

    Cipher Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Cipher Pharmaceuticals does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for CPH.
  • Search Interest

    4 people have searched for CPH on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cipher Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    42.00% of the stock of Cipher Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 3.24% of the stock of Cipher Pharmaceuticals is held by institutions.

  • Read more about Cipher Pharmaceuticals' insider trading history.
Receive CPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cipher Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CPH Stock News Headlines

Why More Investors Are Using Family Trusts to Protect Their Wealth
For many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensuring wealth is passed on according to your wishes. Trusts may also provide shielding from creditors and lawsuits while offering potential tax advantages—especially with estate tax thresholds set to decrease in 2026. If you’re considering whether a family trust is right for you, speaking with a fiduciary financial advisor can help you decide the best path forward. We’ve created a free tool that matches you with vetted advisors in your area—each legally bound to act in your best interest.tc pixel
See More Headlines

CPH Stock Analysis - Frequently Asked Questions

Cipher Pharmaceuticals' stock was trading at C$14.32 at the start of the year. Since then, CPH stock has increased by 14.2% and is now trading at C$16.35.

Cipher Pharmaceuticals Inc. (TSE:CPH) released its quarterly earnings data on Thursday, August, 10th. The company reported $0.16 EPS for the quarter, topping analysts' consensus estimates of $0.15 by $0.01. The business had revenue of $7.10 million for the quarter, compared to the consensus estimate of $7.46 million. Cipher Pharmaceuticals had a net margin of 59.92% and a trailing twelve-month return on equity of 17.93%.
Read the conference call transcript
.

Shares of CPH stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cipher Pharmaceuticals investors own include Cipher Pharmaceuticals (CPHRF), Enbridge (ENB), Bellatrix Exploration (BXE), Crescent Point Energy (CPG), Manulife Financial (MFC), Surge Energy (SGY) and Toronto-Dominion Bank (TD).

Company Calendar

Last Earnings
8/10/2023
Today
9/21/2025

Industry, Sector and Symbol

Stock Exchange
TSE
Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Current Symbol
TSE:CPH
Previous Symbol
TSE:DND
CIK
N/A
Fax
N/A
Employees
5
Year Founded
N/A

Price Target and Rating

High Price Target
C$17.00
Low Price Target
C$12.50
Potential Upside/Downside
-9.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
C$0.46
Trailing P/E Ratio
35.54
Forward P/E Ratio
12.67
P/E Growth
N/A
Net Income
C$11.41 million
Net Margins
59.92%
Pretax Margin
N/A
Return on Equity
17.93%
Return on Assets
7.90%

Debt

Debt-to-Equity Ratio
41.22
Current Ratio
2.00
Quick Ratio
2.67

Sales & Book Value

Annual Sales
C$47.59 million
Price / Sales
8.72
Cash Flow
C$4.63 per share
Price / Cash Flow
3.53
Book Value
C$3.96 per share
Price / Book
4.13

Miscellaneous

Outstanding Shares
25,394,000
Free Float
N/A
Market Cap
C$415.19 million
Optionable
Not Optionable
Beta
0.56
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (TSE:CPH) was last updated on 9/21/2025 by MarketBeat.com Staff
From Our Partners